Literature DB >> 28578648

Synthetic Peptide Drugs for Targeting Skin Cancer: Malignant Melanoma and Melanotic Lesions.

Alex N Eberle1, Bhimsen Rout2, Mei Bigliardi Qi2, Paul L Bigliardi3.   

Abstract

BACKGROUND: Peptides play decisive roles in the skin, ranging from host defense responses to various forms of neuroendocrine regulation of cell and organelle function. Synthetic peptides conjugated to radionuclides or photosensitizers may serve to identify and treat skin tumors and their metastatic forms in other organs of the body. In the introductory part of this review, the role and interplay of the different peptides in the skin are briefly summarized, including their potential application for the management of frequently occurring skin cancers. Special emphasis is given to different targeting options for the treatment of melanoma and melanotic lesions. Radionuclide Targeting: α-Melanocyte-stimulating hormone (α-MSH) is the most prominent peptide for targeting of melanoma tumors via the G protein-coupled melanocortin-1 receptor that is (over-)expressed by melanoma cells and melanocytes. More than 100 different linear and cyclic analogs of α-MSH containing chelators for 111In, 67/68Ga, 64Cu, 90Y, 212Pb, 99mTc, 188Re were synthesized and examined with experimental animals and in a few clinical studies. Linear Ac-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-NH2 (NAP-amide) and Re-cyclized Cys- Cys-Glu-His-D-Phe-Arg-Trp-Cys-Arg-Pro-Val-NH2 (Re[Arg11]CCMSH) containing different chelators at the N- or C-terminus served as lead compounds for peptide drugs with further optimized characteristics. Alternatively, melanoma may be targeted with radiopeptides that bind to melanin granules occurring extracellularly in these tumors. Photosensitizer targeting: A more recent approach is the application of photosensitizers attached to the MSH molecule for targeted photodynamic therapy using LED or coherent laser light that specifically activates the photosensitizer. Experimental studies have demonstrated the feasibility of this approach as a more gentle and convenient alternative compared to radionuclides. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Melanocyte-stimulating hormone (MSH); malignant melanoma; melanin-binding peptide; melanocortin-1 receptor (MC1R); metastasis; photodynamic therapy; photosensitizer; radiometal

Mesh:

Substances:

Year:  2017        PMID: 28578648     DOI: 10.2174/0929867324666170605105942

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

1.  Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles.

Authors:  Xiuli Zhang; Feng Chen; Melik Z Turker; Kai Ma; Pat Zanzonico; Fabio Gallazzi; Manankumar A Shah; Austin R Prater; Ulrich Wiesner; Michelle S Bradbury; Michael R McDevitt; Thomas P Quinn
Journal:  Biomaterials       Date:  2020-02-19       Impact factor: 12.479

2.  A Small Peptide Increases Drug Delivery in Human Melanoma Cells.

Authors:  Shirley Tong; Shaban Darwish; Hanieh Hossein Nejad Ariani; Kate Alison Lozada; David Salehi; Maris A Cinelli; Richard B Silverman; Kamaljit Kaur; Sun Yang
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

3.  Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging.

Authors:  Feng Chen; Xiuli Zhang; Kai Ma; Brian Madajewski; Miriam Benezra; Li Zhang; Evan Phillips; Melik Z Turker; Fabio Gallazzi; Oula Penate-Medina; Michael Overholtzer; Mohan Pauliah; Mithat Gonen; Pat Zanzonico; Ulrich Wiesner; Michelle S Bradbury; Thomas P Quinn
Journal:  ACS Appl Mater Interfaces       Date:  2018-01-24       Impact factor: 9.229

4.  Specific Targeting of Melanotic Cells with Peptide Ligated Photosensitizers for Photodynamic Therapy.

Authors:  Paul Lorenz Bigliardi; Bhimsen Rout; Aakanksha Pant; Viknish Krishnan-Kutty; Alex N Eberle; Ramasamy Srinivas; Brendan Adrian Burkett; Mei Bigliardi-Qi
Journal:  Sci Rep       Date:  2017-11-16       Impact factor: 4.379

Review 5.  Cell cycle regulatory markers in melanoma: New strategies in diagnosis and treatment.

Authors:  Negin Afrang; Maryam Honardoost
Journal:  Med J Islam Repub Iran       Date:  2019-09-14

Review 6.  Recognition of Melanocytes in Immuno-Neuroendocrinology and Circadian Rhythms: Beyond the Conventional Melanin Synthesis.

Authors:  Yan-Yan Chen; Li-Ping Liu; Hang Zhou; Yun-Wen Zheng; Yu-Mei Li
Journal:  Cells       Date:  2022-06-30       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.